Bepridil
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | Well absorbed |
| Protein binding | 99% |
| Metabolism | Hepatic, CYP3A4-mediated |
| Elimination half-life | 42 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H34N2O |
| Molar mass | 366.54 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Bepridil (trade name Vascor) is a calcium channel blocker once used to treat angina. It is no longer sold in the United States.
It is nonselective.[1]
It has been discussed as a possible option in the treatment of atrial fibrillation.[2]
It has been implicated in causing the ventricular arrythmia (Torsade de pointes).
References
- ^ Bezprozvanny I, Tsien RW (1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
{{cite journal}}: Unknown parameter|month=ignored (help) - ^ Imai S, Saito F, Takase H; et al. (2008). "Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm" ([dead link]). Circ. J. 72 (5): 709–15. doi:10.1253/circj.72.709. PMID 18441448.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)
External links
 | This article about an amine is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |